News | November 08, 2010

New Quantification Tool Offered for Oncology Treatment Evaluation

November 9, 2010 – In an effort to further promote the utility of PET/CT (positron emission tomography/computed tomography) imaging in assessing the effectiveness of oncology treatments, a new quantification tool is available to support PERCIST (PET response criteria in solid tumors). PERCIST provides standard uptake value (SUV)-based metrics to define response criteria designed to complement the standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Since the introduction of PERCIST, Siemens Healthcare Molecular Imaging created a PET/CT quantification tool to aid in the adoption of PERCIST evaluation criteria. Using a consistent PET protocol and fixed small region of interest, Siemens’ quantification tool evaluates the most active region of a metabolically active tumor to minimize statistical variability and offer the most consistent results. Siemens supports industry initiatives with this software tool that will make PERCIST data available and reproducible for every patient, so that these criteria will be clinically adopted and used in the field.

RECIST is a well established set of rules for determining response to therapy for patients. These criteria were formed on the basis of measuring anatomical changes in tumors using CT imaging. Because PET/CT imaging can detect changes to the tumor at the molecular level, thought leaders in the molecular imaging field introduced PERCIST criteria to use together with RECIST.

While RECIST criteria offer quantifiable data in terms of tumor size, the PERCIST quantification tool creates reproducible, objective results based on metabolic information for tumor trending over time to determine the efficacy of treatment. PERCIST criteria allow treatment response to be measured in the absence of anatomic change through the assessment of metabolic activity, often even before anatomical changes take place. The PERCIST quantification tool evaluates and delineates metabolic information from the tumor. The tool uses an algorithm that automatically identifies peak SUV within a volume of interest, rather than the common single-pixel measure of SUVmax. The PERCIST quantification tool offers a more robust metric that is less susceptible to statistical variation and noise.

For more information: www.siemens.com/healthcare

Related Content

Accuray Launches Synchrony Motion Tracking and Correction Technology for Radixact System
Technology | Image Guided Radiation Therapy (IGRT) | April 24, 2019
Accuray announced the launch of its Synchrony motion tracking and correction technology to be used with the Radixact...
New Study Redefines Therapeutic Dose Guidelines for Non-Small Cell Lung Cancer
News | Lung Cancer | April 23, 2019
Non-small cell lung cancer is a common cancer for both men and women. Many people who are diagnosed with this type of...
Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index

Fig. 1: Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index. (Agarwal et al, Red Journal, 2019) Credit: Elsevier

News | Radiation Therapy | April 22, 2019
April 22, 2019 — A new study finds wide state
Graphic courtesy of Pixabay

Graphic courtesy of Pixabay

Feature | Artificial Intelligence | April 22, 2019 | By Greg Freiherr
...
Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
FDA Clears GE's Deep Learning Image Reconstruction Engine
Technology | Computed Tomography (CT) | April 19, 2019
GE Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) of its Deep Learning Image...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
ASTRO Applauds Introduction of PIMA Patient Protection Bill
News | Radiology Business | April 15, 2019
The American Society for Radiation Oncology (ASTRO) hailed the introduction of federal legislation that would...
Gamma Knife radiosurgery has become the preferred radiation therapy option for patients with brain tumors at facilities like the Northwestern Medicine Cancer Center, pictured here

Gamma Knife radiosurgery has become the preferred radiation therapy option for patients with brain tumors at facilities like the Northwestern Medicine Cancer Center, pictured here. The technology is favored largely for its ability to precisely target tumors while sparing healthy tissue.

Feature | Radiation Oncology | April 11, 2019 | By Jeff Zagoudis
Brain tumors are some of the most complicated forms of cancer to treat due to their extremely sensitive location.